semaglutide for people without diabetes SELECT Trial Semaglutide Shows Secondary Cardiovascular Prevention

10.7554/eLife.86678 2 AjoolabadyA.KaplowitzN.LebeaupinC.KroemerG.KaufmanR

post-disclosure, the licensee can use the know-how freely within the contract terms

Ethics declarations Conflict of interest KS declares no conflicts of interest associated with this manuscript

Central behavioral effects were subsequently shown to be abolished by a non-selective MC3R/MC4R antagonist, confirming receptor-mediated central MCR activation (PMC PMC1572913)

Compound semaglutide and Ozempic contain the identical active pharmaceutical ingredientsemaglutidebut differ fundamentally in their source, manufacturing pathway, and regulatory classification